Slide 1: Courageous Innovation: 1Q 2024 Business Update
—_—_ ~ ocugen. > ee Courageous Innovation Dedicated to Bringing Game-Changing Gene & Cell Therapies and Vaccines to Market and Working Even Harder to Provide Access to Patients Globally 1Q 2024 Business Update May 14, 2024
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, including, but not limited to, strategy, business plans and objectives for Ocugen’s clinical programs, plans and timelines for the preclinical
Slide 3: Leveraging First-in-Class Platforms to Address Serious Unmet Medical Needs
Through Courageous Innovation, We are Leveraging Our First- in-Class Platforms to Address Serious Unmet Medical Needs . OCU400 Phase 3 liMeliGhT clinical trial (broad retinitis pigmentosa) 7 OCU410 Ph1/2 ArMaDa clinical trial (geographic atrophy) . OCU410ST Phi/2 GARDian clinical trial (Stargardt) M
Slide 4: Modifier Gene Therapy - Creating a Paradigm Shift in Gene Therapy
Modifier Gene Therapy - Creating a Paradigm Shift in Gene Therapy v Received FDA clearance of IND amendmentto initiate OCU400 Phase3 clinical trial in retinitis pigmentosa (RP) - First gene therapy trial to receive broad RP indication from FDA EMA provided acceptability of the U.S.-based trial for s
Slide 5: OCU400 Phase 3 Study Design
5 Study Design • Patient with ≥8 years of age with Clinical and Molecular Diagnosis of Retinitis PigmentosaPopulation • BCVA ≤ 75 letters and ≥25 letters (ETDRS Chart) • Able to perform LDNA at ≤ 500 Lux but unable to pass the LDNA at ≤ 0.35 at the Screening visit • Presence of photoreceptors Key El
Slide 6: OCU400: RP & LCA Market Opportunity
OCU400: RP & LCA Market Opportunity OCU400 is designed to address the shortcomings of current gene therapy approaches—a broad spectrum, gene- agnostic approach to genetically diverse inherited retinal diseases and potential one-time therapy for life with a single sub-retinalinjection Retinitis Leber
Slide 7: OCU410 and OCU410ST: Modifier Gene Therapy Continued Clinical Momentum
OCU410 and OCU410ST: Modifier Gene Therapy Continued Clinical Momentum ¥ OCU410 and OCU4IOST modifier gene therapies leverage the nuclear receptor gene RAR-related orphan receptor A (RORA) v Aimtoprovidea potential one-time therapy for life with a single sub-retinal injection Y Dosing underway for O
Slide 8: OCU410 (dry-AMD): Modifier Gene Therapy Continued Clinical Momentum
OCU410 (dry-AMD): Modifier Gene Therapy Continued Clinical Momentum Y Dosing completion of subjects with GA in cohort 1 of OCU410 Phase 1/2 ArMaDa clinical trial vY Dosing completion of subjects with GA in cohort 2 of OCU410 Phase 1/2 ArMaDa clinical trial Upcominganticipated catalyst: Clinical upda
Slide 9: OCU410 Program Overview
OCU410 Program Overview + Assess the safety and efficacy of OCU410 in subjects with geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD) + Single, unilateral subretinal injection using amodifier gene therapy platform + Upto 63 adult subjects * Mild to moderate disease pres
Slide 10: OCU410ST (Stargardt Disease): Modifier Gene Therapy Clinical Momentum
OCU410ST (Stargardt Disease): Modifier Gene Therapy Clinical Momentum ¥ Dosingcompletion of subjects with Stargardt disease in cohort 1 of OCU410ST Phase 1/2 GARDian clinical trial v DSMB approved to proceed dosing with the medium dose of OCU41OST in the dose-escalation phase of the study Upcomingan
Slide 11: • • • • • • • • 𝐦𝐦𝟐 • • • 𝐦𝐦𝟐 •
• • • • • • • • 𝐦𝐦𝟐 • • • 𝐦𝐦𝟐 • • •
Slide 12: Financial Update
Financial Update
Slide 13: Financial Update
Financial Update Three months ended March 31, Statement of Operations 2024 2023 Research and development expense $6.8 $10.2 General and administrative expense 6.4 83 Other income (expense), net 03 (oly Net loss $011.9) $017.3) Net loss per share of common stock — basic and diluted $(0.05) $0.08) Bal
Slide 14: Questions & Answers
Questions & Answers
Slide 15: 2024 Near-Term Targeted Milestones
2024 Near-Term Targeted Milestones * — Initiate OCU400 Ph3 clinical trial and recruit efficiently — in line with 2026 BLA/MAA approval target * OCU400 Ph3 clinical updates * Preliminary safety/efficacy updates - OCU410 Ph1/2 clinical trial (GA) * Preliminary safety/efficacy updates - OCU410ST Phi1/2
Slide 16: Ocugen Vision
Ocugen™ Vision Fully integrated, patient-centric biotech company focused on vaccines in support of public health and gene and cell therapies targeting unmet medical needs through Courageous Innovation — ocugen. <—